Nuvation Bio to head to FDA with pooled ROS1-positive lung cancer data

Max Gelman

Senior Editor

Nuvation Bio outlined pooled data from its two Phase 2 studies at the annual European Society for Medical Oncology confab in Barcelona this weekend as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Nuvation Bio to head to FDA with pooled ROS1-positive lung cancer data

Max Gelman

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

All of 23andMe's independent board members resign over disagreements with CEO

Bad trip: How culture conflict and a need for cash nearly broke Lykos

Novartis’ Kisqali snags FDA approval to reduce recurrence in patients with early forms of breast cancer

After landing a key win in a common cancer condition, Pfizer faces a big test in Phase 3

Merck and Daiichi’s rejected HER3 ADC clears a Phase 3 in certain lung cancers

Breaking down silos with a new quantitative approach to drug development

Nu­va­tion Bio to head to FDA with pooled ROS1-pos­i­tive lung can­cer da­ta

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Nuvation Bio to head to FDA with pooled ROS1-positive lung cancer data